- Kim et al. In vivo metabotropic glutamate receptor 5 availability-associated functional connectivity alterations in drug-naive young adults with major depression. European Neuropsychopharmacology. 2019;29(2):278-290

- Kim et al. Relationship of self-transcendence traits with in vivo dopamine D2/3 receptor availability and functional connectivity: An [(18)F]fallypride PET and fMRI study. Synapse. 2019 Nov;73(11):e22121. doi: 10.1002/syn.22121.

- Phung et al. Reliable and quantitative SERS detection of dopamine levels in human blood plasma using a plasmonic Au/Ag nanocluster substrate. Nanoscale. 2018 Dec;10(47):22493-22503

- Kim et al. Penalized PET reconstruction using deep learning prior and local linear fitting. IEEE Trans Med Imaging. 2018 ;37(6):1478-1487

- Kim et al. Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [18F]fallypride PET and functional MRI study. Synapse. 2018 Dec;72(12):e22064. doi: 10.1002/syn.22064.

- Kim et al. Neural signature for auditory hallucinations in schizophrenia: a high-resolution positron emission tomography study with fludeoxyglucose (18F). Clin Psychopharmacol Neurosci. 2018;16(3):324-332

- Phung et al. Gold nanostructures electrodeposited on graphene oxide-modified indium tin oxide glass as a surface-enhanced Raman scattering-active substrate for ultrasensitive detection of dopamine neurotransmitter. Japanese Journal of Applied Physics 2018;57:08PF02

- Joo YH et al. The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: A high-resolution PET study with [18F]fallypride. European Archives of Psychiatry and Clinical Neuroscience 2018 Sep;268(6):529-540.

- Kim JH et al. Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study. Psychopharmacology (Berl). 2017 Jun;234(12):1923-1932.

- Kim JH et al. Altered interregional correlations between serotonin transporter availability and cerebral glucose metabolism in schizophrenia: A high-resolution PET study using [11C]DASB and [18F]FDG. Schizophrenia Research 2017 Apr;182:55-65.

- Shin Y et al. Self-perceived cognitive deficits and their relationship with internalized stigma and quality of life in patients with schizophrenia. Neuropsychiatr Dis Treat. 2016;12:1411-1417.

- Kinoshita et al. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016;233(14):2663-2674

- Lee et al. Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study. Psychiatry Investig. 2017; 14(1):44-50

- Kim et al. Diminished autonomic neurocardiac function in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2016;12:3111-3118.

- Kang NI et al. Efficacy and tolerability of paliperidone extended-release in the treatment of first-episode psychosis: an eight-week, open-label, multicenter trial. Clin Psychopharmacol Neurosci 2016;14(3):261-269.

- Kim JH et al. Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: an ultra-high resolution PET-MRI study. Brain Research 2015;1629:63-71

- Kim JH et al. Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:2041-8.

- Kim JH et al. Serotonin transporter availability in thalamic subregions in schizophrenia: a study using 7.0-T MRI with [(11)C]DASB high-resolution PET. Psychiatry Research 2015;231:50-57.

- Son YD et al. Individually differentiated serotonergic raphe nuclei measured with brain PET/MR imaging. Radiology 2014;272(2):541-548.

- Kim JH et al. Effects of clozapine on heart rate dynamics and their relationship with therapeutic response in treatment-resistant schizophrenia.

Journal of Clinical Psychopharmacology 2013;33(1):69-73

- Kim JH et al. Anomalous subjective experiences in schizophrenia, bipolar disorder, and unipolar depression. Comprehensive Psychiatry 2013;54(5):447-453

- Kim JH et al. Dopamine D(2/3) receptor availability and human cognitive impulsivity: a high-resolution positron emission tomography imaging study with [11C]raclopride. Acta Neuropsychiatrica 2014;26(1):35-42.

- Kim JH et al. Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine. Comprehensive Psychiatry 2014;55(3):708-713

- Park JI et al. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. Int Clin Psychopharmacol. 2014;29(2):77-85.

- Kim JH et al. Relationship of oestrogen receptor status to depressive symptoms and quality of life in breast cancer patients. Acta Neuropsychiatrica 2013;25(5):283-288.

- Kim JH et al. Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia. Neuropsychiatr Dis Treat. 2013;9:989-94.

- Kim JH et al. Evaluation of the factor structure of symptoms in patients with schizophrenia. Psychiatry Research 2012;197(3):285-289

- Kim JH, et al. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C] raclopride. Journal of Clinical Psychopharmacology 2011;31:507-511

- Kim JH, et al. Effects of age on dopamine D2 receptor availability in striatal subdivisions: A high-resolution positron emission tomography study. European Neuropsychopharmacology 2011;21(12):885-891

- Kim JH, et al. Association of harm avoidance with dopamine D2/3 receptor availability in striatal subdivisions: A high resolution PET study. Biol Psychol 2011;87(1):164-167.

- Bullich S, et al. Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand (11)C-GSK931145 Determined from Primate and Human Whole-Body PET. Mol Imaging Biol. 2011;13(4):776-84.

- Park HY et al. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012;36:318-323.

- Lee JS, et al. Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia. Clinical Neuropharmacology 2011;34:186-190.

- Kim JH. Subjective experiences in schizophrenia. Australian and New Zealand Journal of Psychiatry 2011;45(3):262.

- Kim JH, et al. Relationship between heart rate variability and the severity of psychotic symptoms in schizophrenia. Acta Neuropsychiatrica 2011;23(4):161-166

- Lee YW, et al. Subjective well-being in patients with schizophrenia treated with atypical antipsychotics. Clinical Psychopharmacology and Neuroscience 2010;8:130-136

- Kim JH, et al. Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment. J Clin Pharm Ther 2011;36(6):687-694.

- Kim JH, et al. Relationship between subjective experiences and psychopathological dimensions in schizophrenia. Aust N Z J Psychiatry. 2010;44(10):952-957.

- Kim JH, Byun HJ. The relationship between akathisia and subjective tolerability in patients with schizophrenia. Int J Neurosci 2010;120(7):507-511

- Kim JH, et al. Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. J Clin Pharm Ther 2011;36(2):172-178

- Kim JH, et al. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia. Compr Psychiatry 2010;51:165-170

- Bae et al. Gender difference in the association between adult attention deficit hyperactivity disorder symptoms and morningness?eveningness. Psychiatry Clin Neurosci. 2010;64:649-51.

- Kim JH, et al. The pNNx heart rate variability statistics: an application to clozapine-treated subjects. Psychiatry Investigation 2009;6:294-298

- Kim JH, et al. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clinical Neuropharmacology 2009;32(5):250-253

- Kim JH, Byun HJ. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Human Psychopharmacology-Clinical and Experimental 2009;24:129-133.

- Chang JS, et al. Stabilization of the internal structure of persistent auditory verbal hallucinations in schizophrenia. Australian and New Zealand Journal of Psychiatry 2009;43:244-251.

- Kegeles LS, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008:33(13):3111-25

- Jeong SH, et al. A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. J Clin Psychopharmacol. 2008;28:618-24.

- Martinez D, Kim JH, Krystal J, Abi-Dargham A. Imaging the neurochemistry of alcohol and substance abuse. Neuroimaging Clinics of North America 2007:17(4):539-55.

- Jung HY, et al. Measuring psychosis proneness in a nonclinical Korean population: is the Peters et al Delusions Inventory useful for assessing high-risk individuals? Compr Psychiatry. 2008;49(2):202-210.

- Kim JH, Kim SY, Byun HJ. Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism & Related Disorders 2008;14(3):239-42.

- Kim JH, Byun HJ. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. Journal of Clinical Pharmacy and Therapeutics 2007:32:461-467

- Kim JH, Park CY, Lee SJ. Effects of Sun Ginseng on subjective quality of life in cancer patients: A double-blind, placebo-controlled pilot trial. Journal of Clinical Pharmacy and Therapeutics 2006:31(4):331-334

- Kim JH, Yi SH, Park KT, Ahn YM, Lee KY, Yang SA, Kim YS. Diminished Neurocardiac Dynamics Associated With Antipsychotic-induced Extrapyramidal Syndrome. European Neuropsychopharmacology 2006:16(6):459-463

- Kim JH, Kim SY, Ahn YM, Kim YS. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006:30(2):301-305

- Kim JH, Jin YH, Kang UG, Ahn YM, Ha KS, Kim YS. Neuroleptic-induced acute and chronic akathisia: a clinical comparison. Movement Disorders 2005:20(12):1667-1670

- Ahn YM, et al. Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment. Int Clin Psychopharmacol. 2005;20(3):157-161.

- Jung HY, et al. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Human Psychopharmacology-Clinical and Experimental. 2005;20(1):41-45.

- Kim JH, Cho SY, Byun HJ, Kang UG, Ahn YM, Kim YS. Multidimensional sensory phenomena in antipsychotic-induced akathisia. Journal of Clinical Psychopharmacology. 2004:24(6):618-623.

- Kim JH, et al. Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004:28(2):371-378

- Kim JH, Byun HJ. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clinical Neuropharmacology 2003:26(6):312-316

- Kim JH, et al. Subjective emotional experience and cognitive impairment in drug-induced akathisia. Comprehensive Psychiatry 2002:43(6):456-462

- Kim JH, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical rating scale for drug-induced movement disorders. Movement Disorders 2002:17(6):1354-1359

International Editorial Board

Australian and New Zealand Journal of Psychiatry (2011-present, SCI IF: 5.084)